Systematic review and meta-analysis of serotonin transporter genotype and discontinuation from antidepressant treatment

European Neuropsychopharmacology

Volumn 23, Issue 10, 2013, Pages 1143-1150

  Crawford, Andrew A ^a   Lewis, Glyn ^a   Lewis, Sarah J ^a   Munafò, Marcus R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

5 HTTLPR; Antidepressant; Discontinuation; Meta analysis; SSRI

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN TRANSPORTER; SEROTONIN TRANSPORTER GENE LINKED POLYMORPHIC REGION; SERTRALINE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; ASIAN; DRUG EFFICACY; DRUG WITHDRAWAL; EUROPEAN AMERICAN; GENE EXPRESSION; GENOTYPE; HOMOZYGOSITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

5-HTTLPR; ANTIDEPRESSANT; DISCONTINUATION; META-ANALYSIS; SSRI;

ALLELES; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSION; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; HUMANS; NERVE TISSUE PROTEINS; NEURONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84884287492     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.12.001     Document Type: Article

References (55)

1. Bellivier F., Henry C., Szoke A., Schurhoff F., Nosten-Bertrand M., Feingold J., Launay J.M., Leboyer M., Laplanche J.L. Serotonin transporter gene polymorphisms in patients with unipolar or bipolar depression. Neurosci. Lett. 1998, 255:143-146.
2. Cipriani A., Furukawa T.A., Salanti G., Geddes J.R., Higgins J.P.T., Churchill R., Watanabe N., Nakagawa A., Omori I.M., McGuire H., Tansella M., Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-758.
3. Clarke H., Flint J., Attwood A.S., Munafo M.R. Association of the 5-HTTLPR genotype and unipolar depression: a meta-analysis. Psychol. Med. 2010, 40:1767-1778.
4. Demyttenaere K., Enzlin P., Dewe W., Boulanger B., De Bie J., De Troyer W., Mesters P. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J. Clin. Psychiatry 2001, 62:30-33.
5. Dogan O., Yuksel N., Ergun M.A., Yilmaz A., Ilhan M.N., Karslioglu H.E., Koc A., Menevse A. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet. Test. 2008, 12:225-231.
6. Donoghue J., Tylee A., Wildgust H. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5. Br. Med. J. 1996, 313:861-862.
7. Durham L.K., Webb S.M., Milos P.M., Clary C.M., Seymour A.B. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology 2004, 174:525-529.
8. Egger M., Smith G.D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 1997, 315:629-634.
9. Ferguson J.M. SSRI antidepressant medications: adverse effects and tolerability. Primary care Companion J. Clin. Psychiatry 2001, 3:22.
10. Gressier F., Bouaziz E., Verstuyft C., Hardy P., Becquemont L., Corruble E. 5-HTTLPR modulates antidepressant efficacy in depressed women. Psychiatr. Genet. 2009, 19:195-200.
11. Gudayol-Ferre E., Herrera-Guzman I., Camarena B., Cortes-Penagos C., Herrera-Abarca J.E., Martinez-Medina P., Cruz D., Hernandez S., Genis A., Carrillo-Guerrero M.Y., Aviles Reyes R., Guardia-Olmos J. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. J. Affect. Disord. 2010, 127:343-351.
12. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 2009, 61:105-123.
13. Hauser J., Leszczynska A., Samochowiec J., Czerski P.M., Ostapowicz A., Chlopocka M., Horodnicki J., Rybakowski J.K. Association analysis of the insertion/deletion polymorphism in serotonin transporter gene in patients with affective disorder. Eur. Psychiatry 2003, 18:129-132.
14. Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Br. Med. J. 2003, 327:557-560.
15. Higuchi H., Takahashi H., Kamata M., Yoshida K. Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression. Neuropsychiatr. Dis. Treat. 2009, 5:393-398.
16. Hranilovic D., Stefulj J., Schwab S., Borrmann-Hassenbach M., Albus M., Jernej B., Wildenauer D. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol. Psychiatry 2004, 55:1090-1094.
17. Hu X.Z., Lipsky R.H., Zhu G.S., Akhtar L.A., Taubman J., Greenberg B.D., Xu K., Arnold P.D., Richter M.A., Kennedy J.L., Murphy D.L., Goldman D. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 2006, 78:815-826.
18. Hu X.Z., Rush A.J., Charney D., Wilson A.F., Sorant A.J.M., Papanicolaou G.J., Fava M., Trivedi M.H., Wisniewski S.R., Laje G., Paddock S., McMahon F.J., Manji H., Lipsky R.H. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry 2007, 64:783-792.
19. Huezo-Diaz P., Uher R., Smith R., Rietschel M., Henigsberg N., Marusic A., Mors O., Maier W., Hauser J., Souery D., Placentino A., Zobel A., Larsen E.R., Czerski P.M., Gupta B., Hoda F., Perroud N., Farmer A., Craig I., Aitchison K.J., McGuffin P. Moderation of antidepressant response by the serotonin transporter gene. Br. J. Psychiatry 2009, 195:30-38.
20. Illi A., Poutanen O., Setälä-Soikkeli E., Kampman O., Viikki M., Huhtala H., Mononen N., Haraldsson S., Koivisto P., Leinonen E., Lehtimäki T. Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 1-8.
21. Illi A., Poutanen O., Setala-Soikkeli E., Kampman O., Viikki M., Huhtala H., Mononen N., Haraldsson S., Koivisto P.A., Leinonen E., Lehtimaki T. Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261:95-102.
22. Joiner T.E., Johnson F., Soderstrom K., Brown J.S. Is there an association between serotonin transporter gene polymorphism and family history of depression?. J. Affect. Disord. 2003, 77:273-275.
23. Joyce P.R., Mulder R.T., Luty S.E., McKenzie J.M., Miller A.L., Rogers G.R., Kennedy M.A. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta 3 subunit as predictors of response to fluoxetine and nortriptyline. Int. J. Neuropsychopharmacol. 2003, 6:339-346.
24. Kang R.H., Kim J.G., Choi M.J., Lee H.W., Kang S.G., Lee H.J., Lee M.S. Association study of the 5-HTT polymorphism and mirtazapine antidepressant response in major depressive disorder. Eur. Neuropsychopharmacol. 2007, 17:S322-S323.
25. Kang R.H., Wong M.L., Choi M.J., Paik J.W., Lee M.S. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31:1317-1321.
26. Kato M., Fukuda T., Wakeno M., Fukuda K., Okugawa G., Ikenaga Y., Yamashita M., Takekita Y., Nobuhara K., Azuma J., Kinoshita T. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006, 53:186-195.
27. Kato M., Ikenaga Y., Wakeno M., Okugawa G., Nobuhara K., Fukuda T., Fukuda K., Azuma J., Kinoshita T. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int. Clin. Psychopharmacol. 2005, 20:151-156.
28. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry 2010, 15:473-500.
29. Kronenberg S., Apter A., Brent D., Schirman S., Melhem N., Pick N., Gothelf D., Carmel M., Frisch A., Weizman A. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. J. Child Adolesc. Psychopharmacol. 2007, 17:741-750.
30. Kunugi H., Hattori M., Kato T., Tatsumi M., Sakai T., Sasaki T., Hirose T., Nanko S. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol. Psychiatry 1997, 2:457-462.
31. Lanctot K.L., Rapoport M.J., Chan F., Rajaram R.D., Strauss J., Sicard T., McCullagh S., Feinstein A., Kiss A., Kennedy J.L., Bassett A.S., Herrmann N. Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. Brain Inj. 2010, 24:959-969.
32. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
33. Lewis G., Mulligan J., Wiles N., Cowen P., Craddock N., Ikeda M., Grozeva D., Mason V., Nutt D., Sharp D. Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. Br. J. Psychiatry 2011, 198:464.
34. Maron E., Tammiste A., Kallassalu K., Eller T., Vasar V., Nutt D.J., Metspalu A. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur. Neuropsychopharmacol. 2009, 19:451-456.
35. Montgomery S.A., Bebbington P., Cowen P., Deakin W., Freeling P., Hallstrom C., Katona C., King D., Leonard B. Guidelines for treating depressive illness with antidepressants: a statement from the British Association for Psychopharmacology. J. Psychopharmacol. 1993, 7:19-23.
36. Murphy G.M., Hollander S.B., Rodrigues H.E., Kremer C., Schatzberg A.F. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry 2004, 61:1163-1169.
37. Murthy N.V., Selvaraj S., Cowen P.J., Bhagwagar Z., Riedel W.J., Peers P., Kennedy J.L., Sahakian B.J., Laruelle M.A., Rabiner E.A., Grasby P.M. Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to C-11 DASB binding in the living human brain. Neuroimage 2010, 52:50-54.
38. Ng C.H., Easteal S., Tan S., Schweitzer I., Ho B.K.W., Aziz S. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2006, 30:953-957.
39. Parsey R.V., Hastings R.S., Oquendo M.A., Hu X.Z., Goldman D., Huang Y.Y., Simpson N., Arcement J., Ogden R.T., Van Heertum R.L., Arango V., Mann J.J. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am. J. Psychiatry 2006, 163:48-51.
40. Perlis R.H., Mischoulon D., Smoller J.W., Wan Y.J.Y., Lamon-Fava S., Lin K.M., Rosenbaum J.F., Fava M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry 2003, 54:879-883.
41. Porcelli S., Fabbri C., Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur. Neuropsychopharmacol. 2012, 22:239-258.
42. Ruhe H.G., Ooteman W., Booij J., Michel M.C., Moeton M., Baas F., Schene A.H. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet. Genomics 2009, 19:67-76.
43. Saeki Y., Watanabe T., Ueda M., Saito A., Akiyama K., Inoue Y., Hirokane G., Morita S., Yamada N., Shimoda K. Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. Eur. J. Clin. Pharmacol. 2009, 65:685-691.
44. Safarinejad M.R. Analysis of association between the 5-HTTLPR and STin2 polymorphisms in the serotonin-transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation. BJU Int. 2010, 105:73-78.
45. Serretti A., Mandelli L., Lorenzi C., Pirovano A., Olgiati P., Colombo C., Smeraldi E. Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Res. 2007, 149:185-193.
46. StataCorp, 2011. Stata Statistical Software. StataCorp LP, College Station, TX.
47. Sterne J.A.C., Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J. Clin. Epidemiol. 2001, 54:1046-1055.
48. Takahashi H., Yoshida K., Ito K., Sato K., Kamata M., Higuchi H., Shimizu T., Inoue K., Tezuka T., Suzuki T., Ohkubo T., Sugawara K. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur. Neuropsychopharmacol. 2002, 12:477-481.
49. Tanaka M., Kobayashi D., Murakami Y., Ozaki N., Suzuki T., Iwata N., Haraguchi K., Ieiri I., Kinukawa N., Hosoi M., Ohtani H., Sawada Y., Mine K. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int. J. Neuropsychopharmacol. 2008, 11:261-267.
50. Taylor M.J., Sen S., Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol. Psychiatry 2010, 68:536-543.
51. Uher R. The implications of gene-environment interactions in depression: will cause inform cure?. Mol. Psychiatry 2008, 13:1070-1078.
52. Umene-Nakano W., Yoshimura R., Ueda N., Suzuki A., Ikenouchi-Sugita A., Hori H., Otani K., Nakamura J. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J. Psychopharmacol. 2010, 24:1764-1771.
53. Vidal R., Valdizan E.M., Mostany R., Pazos A., Castro E. Long-term treatment with fluoxetine induces desensitization of 5-HT4 receptor-dependent signalling and functionality in rat brain. J. Neurochem. 2009, 110:1120-1127.
54. Yoshimura R., Umene-Nakano W., Suzuki A., Ueda N., Miyamoto K., Ikenouchi-Sugita A., Hori H., Otani K., Nakamura J. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Human Psychopharmacol.-Clin. Exp. 2009, 24:489-494.
55. Yuksel N., Dogan O., Ergun M.A., Karslioglu H.E., Koc A., Yilmaz A., Ilhan M.N., Menevse A. Correlation between SERT polymorphisms and Venlafaxine response in major depression patients. Genes Genomics 2010, 32:217-223.